share_log

ASLAN Says 'The Eblasakimab 400mg Q4W Dosing Arm Did Not Meet the Primary or Secondary Endpoints With Statistical Significance'

Benzinga ·  Jul 6, 2023 07:59
ASLAN Says 'The eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance'
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment